ImageneBio, Inc. Research and Development Expense
ImageneBio, Inc. (IMA) reported Research and Development Expense of $6.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- ImageneBio, Inc. research and development expense for the quarter ending 2026-06-30 was $6.67M, a 17.97% increase year-over-year.
- ImageneBio, Inc. research and development expense for the quarter ending 2026-03-31 was $5.96M, a 47.55% increase year-over-year.
- ImageneBio, Inc. research and development expense for the quarter ending 2025-12-31 was $3.27M, a 12.90% decline year-over-year.
- ImageneBio, Inc. research and development expense for the quarter ending 2025-09-30 was $15.56M, a 300.46% increase year-over-year.
- ImageneBio, Inc. research and development expense for fiscal 2025 was $28.52M, a 11.16% decline from fiscal 2024.
- ImageneBio, Inc. research and development expense for fiscal 2024 was $32.11M, a 46.17% decline from fiscal 2023.
- ImageneBio, Inc. research and development expense for fiscal 2023 was $59.65M, a 7.26% decline from fiscal 2022.
- ImageneBio, Inc. research and development expense for fiscal 2022 was $64.32M, a 36.54% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.67M 10-Q · filed 2026-08-05 | $12.63M 10-Q · filed 2026-08-05 | $15.90M derived: sum of 3 quarters · filed 2026-08-05 | $31.46M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $5.96M 10-Q · filed 2026-05-07 | $9.23M derived: sum of 2 quarters · filed 2026-05-07 | $24.79M derived: sum of 3 quarters · filed 2026-05-07 | $30.45M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $3.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $18.83M derived: sum of 2 quarters · filed 2026-03-10 | $24.48M derived: sum of 3 quarters · filed 2026-08-05 | $28.52M 10-K · filed 2026-03-10 | ||||
| 2025-09-30 | $15.56M 10-Q · filed 2025-11-12 | $21.21M derived: sum of 2 quarters · filed 2026-08-05 | $25.25M 10-Q · filed 2025-11-12 | $29.01M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $5.65M 10-Q · filed 2026-08-05 | $4.03M 10-Q · filed 2025-07-24 | $9.69M 10-Q · filed 2026-08-05 | $7.74M 10-Q · filed 2025-07-24 | $13.45M derived: sum of 3 quarters · filed 2026-08-05 | $17.34M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $4.04M 10-Q · filed 2026-05-07 | $3.71M 10-Q · filed 2025-05-08 | $7.80M derived: sum of 2 quarters · filed 2026-05-07 | $11.68M derived: sum of 3 quarters · filed 2026-05-07 | $21.52M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $3.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $7.64M derived: sum of 2 quarters · filed 2026-03-10 | $17.48M derived: sum of 3 quarters · filed 2026-03-10 | $32.11M 10-K · filed 2026-03-10 | $30.88M 10-K · filed 2025-03-06 | |||
| 2024-09-30 | $3.88M 10-Q · filed 2025-11-12 | $6.82M 10-Q · filed 2024-11-07 | $13.72M derived: sum of 2 quarters · filed 2025-11-12 | $28.35M 10-Q · filed 2025-11-12 | $26.30M 10-Q · filed 2024-11-07 | $37.64M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $9.83M 10-Q · filed 2025-07-24 | $19.48M 10-Q · filed 2025-07-24 | $33.75M derived: sum of 3 quarters · filed 2025-07-24 | $48.41M derived: sum of 4 quarters · filed 2025-07-24 | ||||
| 2024-03-31 | $9.64M 10-Q · filed 2025-05-08 | $23.92M derived: sum of 2 quarters · filed 2025-05-08 | $38.57M derived: sum of 3 quarters · filed 2025-05-08 | $53.74M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $14.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $28.93M derived: sum of 2 quarters · filed 2025-03-06 | $44.10M derived: sum of 3 quarters · filed 2025-03-06 | $59.65M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | $14.65M 10-Q · filed 2024-11-07 | $29.83M derived: sum of 2 quarters · filed 2024-11-07 | $45.38M 10-Q · filed 2024-11-07 | $61.02M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $15.17M 10-Q · filed 2024-08-08 | $30.72M 10-Q · filed 2024-08-08 | $46.36M derived: sum of 3 quarters · filed 2024-08-08 | $65.21M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $15.55M 10-Q · filed 2024-05-13 | $31.19M derived: sum of 2 quarters · filed 2024-05-13 | $50.04M derived: sum of 3 quarters · filed 2024-05-13 | $65.53M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | $15.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $34.49M derived: sum of 2 quarters · filed 2024-03-12 | $49.98M derived: sum of 3 quarters · filed 2024-03-12 | $64.32M 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | $18.85M 10-Q · filed 2023-11-09 | $34.34M derived: sum of 2 quarters · filed 2023-11-09 | $48.68M 10-Q · filed 2023-11-09 | $61.02M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | $15.49M 10-Q · filed 2023-08-10 | $29.83M 10-Q · filed 2023-08-10 | $42.17M derived: sum of 3 quarters · filed 2023-08-10 | $55.54M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $14.34M 10-Q · filed 2023-05-15 | $26.68M derived: sum of 2 quarters · filed 2023-05-15 | $40.06M derived: sum of 3 quarters · filed 2023-05-15 | $51.43M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $12.34M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $25.71M derived: sum of 2 quarters · filed 2023-03-14 | $37.09M derived: sum of 3 quarters · filed 2023-03-14 | $47.11M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | $13.38M 10-Q · filed 2022-11-07 | $24.75M derived: sum of 2 quarters · filed 2022-11-07 | $34.77M 10-Q · filed 2022-11-07 | $58.17M derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2021-06-30 | $11.37M 10-Q · filed 2022-08-11 | $21.40M 10-Q · filed 2022-08-11 | $44.80M derived: sum of 3 quarters · filed 2022-08-11 | $52.02M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $10.02M 10-Q · filed 2022-05-12 | $33.42M derived: sum of 2 quarters · filed 2022-05-12 | $40.64M derived: sum of 3 quarters · filed 2022-05-12 | $46.98M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $23.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $30.62M derived: sum of 2 quarters · filed 2022-03-17 | $36.95M derived: sum of 3 quarters · filed 2022-03-17 | $44.85M 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $7.22M 10-Q · filed 2021-11-10 | $13.55M derived: sum of 2 quarters · filed 2021-11-10 | $21.45M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $6.33M 10-Q · filed 2021-08-12 | $14.23M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $7.89M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |